Literature DB >> 12012270

Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.

A Thum1, K Hupe-Sodmann, R Göke, K Voigt, B Göke, G P McGregor.   

Abstract

These in vitro studies aimed to characterize the pattern and the kinetics of endoproteolysis of the insulinotropic hormone glucagon-like peptide-1 (GLP-1) and related peptides by native ectopeptidases. Peptides were incubated with isolated rat or pig kidney brush-border microvilli membranes, which are a rich source of the ectopeptidases that are responsible for the post-secretory metabolism of peptide hormones. The proteolytic products were separated by reversed-phase HPLC column chromatography and characterised by molecular mass and primary structure. The relative importance of specific peptidases was established by measuring the effects of specific peptidase inhibitors on the kinetics of proteolysis. Dipeptidyl-peptidase-IV was found to be rate-limiting in the endoproteolysis of GLP-1. GLP-1 homologs, exendins-3 and -4, exhibited exceptional stability in the presence of isolated kidney microvilli membranes. Our finding that exendin-4 is several orders of magnitude more stable than GLP-1 and Ser-8-GLP-1 is especially noteworthy given this peptide's widely reported insulinotropic potency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12012270     DOI: 10.1055/s-2002-29087

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  16 in total

1.  A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.

Authors:  Suleiman Al-Sabah; Dan Donnelly
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 2.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 3.  GLP-1 and energy balance: an integrated model of short-term and long-term control.

Authors:  Jason G Barrera; Darleen A Sandoval; David A D'Alessio; Randy J Seeley
Journal:  Nat Rev Endocrinol       Date:  2011-06-07       Impact factor: 43.330

4.  Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.

Authors:  L Simonsen; J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2006-01-31       Impact factor: 10.122

5.  In vivo biological activity of exendin (1-30).

Authors:  Máire E Doyle; Patrick McConville; Michael J Theodorakis; Margaret M Goetschkes; Michel Bernier; Richard G S Spencer; Harold W Holloway; Nigel H Greig; Josephine M Egan
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

6.  The role of incretins in cardiovascular control.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

7.  Improved human islet preparations using glucocorticoid and exendin-4.

Authors:  Atsushi Miki; Camillo Ricordi; Toshiyuki Yamamoto; Yasunaru Sakuma; Ryosuke Misawa; Atsuyoshi Mita; Luca Inverardi; Rodolfo Alejandro; Hirohito Ichii
Journal:  Pancreas       Date:  2014-11       Impact factor: 3.327

8.  Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells.

Authors:  Q Wang; L Li; E Xu; V Wong; C Rhodes; P L Brubaker
Journal:  Diabetologia       Date:  2004-02-05       Impact factor: 10.122

Review 9.  Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 10.  Battle of GLP-1 delivery technologies.

Authors:  Minzhi Yu; Mason M Benjamin; Santhanakrishnan Srinivasan; Emily E Morin; Ekaterina I Shishatskaya; Steven P Schwendeman; Anna Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2018-07-21       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.